Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in...
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for...
ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today...
NavaMD’s clinically studied, OTC skincare platform is protected by a global intellectual property portfolio and $50+ Million of third-party capital...
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery,...
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class...
-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel...
Progressive Care is pleased to announce that the Company has scheduled an investor conference call at 4:30 PM ET on...
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rdat 9:00...
Brian Cage Brian CageATLANTA, GA , March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Avra, Inc. (OTC PINK: SPRJ),...
Westport, CT, March 23, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology...
MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company focused on discovering, developing, and...
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated...
TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce that...
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post...
-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI...
- Expands Corporate Clinic Opportunity in the Northeast Region - SCOTTSDALE, Ariz., March 23, 2022 (GLOBE NEWSWIRE) -- The Joint...
The randomized cross-over clinical trial assessed the new Provox® Life™ System for pulmonary rehabilitation and quality of life after total...
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an...
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was...
